FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321885493> ?p ?o ?g. }

• W2321885493 endingPage "399" @default.
• W2321885493 startingPage "392" @default.
• W2321885493 abstract "Nuclear factor erythroid 2-related factor 2 (NRF2) has been shown to protect against experimental sepsis in mice and lipopolysaccharide (LPS)-induced inflammation in ex vivo white blood cells from healthy subjects by upregulating cellular antioxidant genes. The objective of this study was to test the hypothesis that ex vivo methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate (CDDO-Me) activates NRF2-regulated antioxidant genes in white blood cells from patients with septic shock and protects against LPS-induced inflammation and reactive oxidative species production. Peripheral blood was collected from 18 patients with septic shock who were being treated in medical and surgical intensive care units. Real-time polymerase chain reaction was used to quantify the expression of NRF2 target genes (NQO1, HO-1, GCLM, and FTL) and IL-6 in peripheral blood mononuclear cells (PBMCs), monocytes, and neutrophils after CDDO-Me treatment alone or after subsequent LPS exposure. Superoxide anion (O2) was measured to assess the effect of CDDO-Me pretreatment on subsequent LPS exposure. Treatment with CDDO-Me increased the gene expression of NQO1 (P = 0.04) and decreased the expression of HO-1 (P = 0.03) in PBMCs from patients with septic shock. Purified monocytes exhibited significant increases in the expression of NQO1 (P = 0.01) and GCLM (P = 0.003) after CDDO-Me treatment. Levels of other NRF2 target genes (HO-1 and FTL) remained similar to those of vehicle-treated cells. Peripheral blood mononuclear cells showed a trend toward increased IL-6 gene expression after CDDO-Me treatment, whereas purified monocytes showed a trend toward decreased IL-6. There was no discernible trend in the IL-6 expression subsequent to LPS treatment in either vehicle-treated or CDDO-Me-treated PBMCs and monocytes. Treatment with CDDO-Me significantly increased O2 production in PBMCs (P = 0.04). Although CDDO-Me pretreatment significantly attenuated O2 production to subsequent LPS exposure (P = 0.03), the change was comparable to that observed in vehicle-treated PBMCs. Pretreatment with CDDO-Me followed by LPS exposure had no significant effect on O2 levels in purified monocytes. These data suggest that the NRF2 pathway is differentially responsive to CDDO-Me activation in peripheral blood cells from patients with septic shock and results in increased O2 production. The data may also suggest a suppressed NRF2 pathway in white blood cells from critically ill patients." @default.
• W2321885493 created "2016-06-24" @default.
• W2321885493 creator A5015765938 @default.
• W2321885493 creator A5053861652 @default.
• W2321885493 creator A5081578838 @default.
• W2321885493 creator A5085233493 @default.
• W2321885493 date "2014-11-01" @default.
• W2321885493 modified "2023-10-17" @default.
• W2321885493 title "The Effect of Ex Vivo CDDO-Me Activation on Nuclear Factor Erythroid 2–Related Factor 2 Pathway in White Blood Cells From Patients With Septic Shock" @default.
• W2321885493 cites W1738483406 @default.
• W2321885493 cites W1816168801 @default.
• W2321885493 cites W1966017556 @default.
• W2321885493 cites W1982470582 @default.
• W2321885493 cites W1987056806 @default.
• W2321885493 cites W2044078040 @default.
• W2321885493 cites W2045821670 @default.
• W2321885493 cites W2048626433 @default.
• W2321885493 cites W2065397424 @default.
• W2321885493 cites W2072207999 @default.
• W2321885493 cites W2072499657 @default.
• W2321885493 cites W2096261918 @default.
• W2321885493 cites W2100352509 @default.
• W2321885493 cites W2105691693 @default.
• W2321885493 cites W2119367809 @default.
• W2321885493 cites W2124032393 @default.
• W2321885493 cites W2124568143 @default.
• W2321885493 cites W2145161910 @default.
• W2321885493 cites W2146558971 @default.
• W2321885493 cites W2155383113 @default.
• W2321885493 cites W2157579772 @default.
• W2321885493 cites W2161771297 @default.
• W2321885493 cites W2166305525 @default.
• W2321885493 doi "https://doi.org/10.1097/shk.0000000000000236" @default.
• W2321885493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4322931" @default.
• W2321885493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25105464" @default.
• W2321885493 hasPublicationYear "2014" @default.
• W2321885493 type Work @default.
• W2321885493 sameAs 2321885493 @default.
• W2321885493 citedByCount "13" @default.
• W2321885493 countsByYear W23218854932014 @default.
• W2321885493 countsByYear W23218854932015 @default.
• W2321885493 countsByYear W23218854932016 @default.
• W2321885493 countsByYear W23218854932017 @default.
• W2321885493 countsByYear W23218854932018 @default.
• W2321885493 countsByYear W23218854932019 @default.
• W2321885493 countsByYear W23218854932023 @default.
• W2321885493 crossrefType "journal-article" @default.
• W2321885493 hasAuthorship W2321885493A5015765938 @default.
• W2321885493 hasAuthorship W2321885493A5053861652 @default.
• W2321885493 hasAuthorship W2321885493A5081578838 @default.
• W2321885493 hasAuthorship W2321885493A5085233493 @default.
• W2321885493 hasBestOaLocation W23218854931 @default.
• W2321885493 hasConcept C104317684 @default.
• W2321885493 hasConcept C127561419 @default.
• W2321885493 hasConcept C137061746 @default.
• W2321885493 hasConcept C150903083 @default.
• W2321885493 hasConcept C153911025 @default.
• W2321885493 hasConcept C17991360 @default.
• W2321885493 hasConcept C185592680 @default.
• W2321885493 hasConcept C202751555 @default.
• W2321885493 hasConcept C203014093 @default.
• W2321885493 hasConcept C207001950 @default.
• W2321885493 hasConcept C26291073 @default.
• W2321885493 hasConcept C2776252253 @default.
• W2321885493 hasConcept C2776914184 @default.
• W2321885493 hasConcept C2777628635 @default.
• W2321885493 hasConcept C2778384902 @default.
• W2321885493 hasConcept C2778754761 @default.
• W2321885493 hasConcept C2779881523 @default.
• W2321885493 hasConcept C2781173740 @default.
• W2321885493 hasConcept C55493867 @default.
• W2321885493 hasConcept C71924100 @default.
• W2321885493 hasConcept C86803240 @default.
• W2321885493 hasConceptScore W2321885493C104317684 @default.
• W2321885493 hasConceptScore W2321885493C127561419 @default.
• W2321885493 hasConceptScore W2321885493C137061746 @default.
• W2321885493 hasConceptScore W2321885493C150903083 @default.
• W2321885493 hasConceptScore W2321885493C153911025 @default.
• W2321885493 hasConceptScore W2321885493C17991360 @default.
• W2321885493 hasConceptScore W2321885493C185592680 @default.
• W2321885493 hasConceptScore W2321885493C202751555 @default.
• W2321885493 hasConceptScore W2321885493C203014093 @default.
• W2321885493 hasConceptScore W2321885493C207001950 @default.
• W2321885493 hasConceptScore W2321885493C26291073 @default.
• W2321885493 hasConceptScore W2321885493C2776252253 @default.
• W2321885493 hasConceptScore W2321885493C2776914184 @default.
• W2321885493 hasConceptScore W2321885493C2777628635 @default.
• W2321885493 hasConceptScore W2321885493C2778384902 @default.
• W2321885493 hasConceptScore W2321885493C2778754761 @default.
• W2321885493 hasConceptScore W2321885493C2779881523 @default.
• W2321885493 hasConceptScore W2321885493C2781173740 @default.
• W2321885493 hasConceptScore W2321885493C55493867 @default.
• W2321885493 hasConceptScore W2321885493C71924100 @default.
• W2321885493 hasConceptScore W2321885493C86803240 @default.
• W2321885493 hasIssue "5" @default.
• W2321885493 hasLocation W23218854931 @default.
• W2321885493 hasLocation W23218854932 @default.
• W2321885493 hasLocation W23218854933 @default.

• next